Rockville's Supernus Pharmaceuticals wins patents dispute trial

Rockville-based biotech Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) successfully defended several of its patents against a generic challenger this week. The U.S. District Court in New Jersey ruled TWi Pharmaceuticals Inc. and one of its subsidiaries infringed on three of Supernus' patents for its epilepsy drug, Oxtellar XR. Patent challenges are a key threat for the biotech space. In a release filed with the Securities and Exchange Commission thi s week, Supernus said the ruling confirmed the validity…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news